Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib sodium for macular edema secondary to CRVO
NCT00088283Phase 2Completed
- Sponsor
- OSI Eyetech
- Start
- May 2004
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of pegaptanib sodium in macular edema, sponsored by OSI Eyetech. Started May 2004; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT00088283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088283.